- Home
- FOA vs PBYI Comparison
FOA vs PBYI Comparison
Compare FOA & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FOA | PBYI |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.7M | 263.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FOA | PBYI |
|---|---|---|
| Price | $22.85 | $5.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $29.75 | $7.00 |
| AVG Volume (30 Days) | 99.8K | ★ 377.4K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.87 |
| EPS | N/A | ★ 0.74 |
| Revenue | ★ $318,296,000.00 | $211,995,000.00 |
| Revenue This Year | $29.44 | N/A |
| Revenue Next Year | $14.30 | N/A |
| P/E Ratio | ★ N/A | $7.55 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $16.58 | $2.58 |
| 52 Week High | $32.40 | $6.12 |
Technical Indicators
Market Signals| Indicator | FOA | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 46.36 | 57.60 |
| Support Level | $22.20 | $5.48 |
| Resistance Level | $23.99 | $5.73 |
| Average True Range (ATR) | 0.85 | 0.22 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 28.57 | 70.37 |
Price Performance
Historical ComparisonAbout FOA Finance of America Companies Inc.
Finance of America Companies Inc is a financial services holding company that, through its operating subsidiaries, is a modern retirement solutions platform that provides customers with access to a range of retirement offerings centered on the home. In addition, FoA offers capital markets and portfolio management capabilities to optimize the distribution of its originated loans to investors. It operates through two segments: Retirement Solutions and Portfolio Management. It generates the majority of its revenue from Retirement Solutions.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.